1. Home
  2. ORI vs TGTX Comparison

ORI vs TGTX Comparison

Compare ORI & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Old Republic International Corporation

ORI

Old Republic International Corporation

HOLD

Current Price

$41.08

Market Cap

10.1B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$55.38

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORI
TGTX
Founded
1923
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
8.5B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
ORI
TGTX
Price
$41.08
$55.38
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$43.50
$49.80
AVG Volume (30 Days)
1.6M
2.5M
Earning Date
04-23-2026
05-04-2026
Dividend Yield
9.47%
N/A
EPS Growth
14.81
1746.67
EPS
1.32
0.12
Revenue
$9,136,300,000.00
$2,785,000.00
Revenue This Year
$7.07
$49.08
Revenue Next Year
$6.86
$26.69
P/E Ratio
$31.52
$439.00
Revenue Growth
10.99
N/A
52 Week Low
$35.60
$25.37
52 Week High
$46.76
$59.30

Technical Indicators

Market Signals
Indicator
ORI
TGTX
Relative Strength Index (RSI) 47.36 46.45
Support Level $40.49 $51.15
Resistance Level $43.36 $58.34
Average True Range (ATR) 0.74 2.29
MACD -0.13 -1.00
Stochastic Oscillator 23.39 6.05

Price Performance

Historical Comparison
ORI
TGTX

About ORI Old Republic International Corporation

Old Republic International Corp is engaged in the business of insurance underwriting and related services. The company operates in two segments: Specialty Insurance and Title Insurance. The insurance provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others. The company generates the majority of its revenue from Specialty Insurance. The Specialty Insurance provides property and liability insurance principally to commercial clients.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: